Every material Form 8-K Niagen Bioscience, Inc. has filed with the SEC since May 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Niagen Bioscience reported third-quarter 2026 results with net sales of $27.2 million, down from $34.0 million a year earlier, and a net loss of $1.2 million, compared with net income of $4.6 million in the prior-year quarter. The company said 2026 is an investment year, expects operating expenses to rise, and expects its ingredient business to be lower than last year, which weighs on shareholders' near-term earnings outlook.
Q3 2026 net sales were $27.2 million, including $23.3 million from Tru Niagen, versus $34.0 million in Q3 2025.
Net loss was $1.2 million, or $(0.01) per share, versus net income of $4.6 million in Q3 2025.
Adjusted EBITDA, a non-GAAP measure, was $0.5 million, versus $6.4 million a year earlier.
Cash and cash equivalents were $69.5 million at September 30, 2026, up from $66.7 million at June 30, 2026.
Niagen Bioscience reported second-quarter 2026 net sales of $29.8 million, down from $31.1 million a year earlier, and net income of $1.0 million, down from $3.6 million. The company expects operating expenses to rise in 2026 as it invests in pharmaceutical, telehealth and skincare initiatives, and it expects its ingredient business to be lower than last year.
Q2 2026 net sales were $29.8 million versus $31.1 million in Q2 2025; Tru Niagen sales were $24.2 million.
Net income was $1.0 million, or $0.01 per diluted share, versus $3.6 million, or $0.04, a year earlier; adjusted EBITDA was $3.0 million versus $5.0 million.
For 2026, e-commerce is expected to grow 10% to 15%, while the ingredient business is expected to be lower than the prior year and operating expenses are expected to increase.
NB4168, a lead investigational therapeutic, received FDA Rare Pediatric Disease designation for Ataxia-Telangiectasia; preclinical studies with Evotec are expected to begin in Q3 2026.
Niagen Bioscience reported first-quarter 2026 net sales of $31.5 million, up 3% from a year earlier, and net income of $6.3 million, up from $5.1 million. Net income includes a $4.8 million gain on the sale of its Analytical Reference Standards and Services segment, while operating income fell to $1.6 million from $4.8 million and adjusted EBITDA fell to $3.8 million from $4.9 million, so shareholders should weigh the one-time gain against weaker core profitability.
Net sales rose 3% to $31.5 million; excluding the divested segment in both periods, sales rose about 5%.
Operating expenses increased 26% to $18.4 million, and operating income fell to $1.6 million from $4.8 million.
Operating cash flow was a $1.2 million outflow, and cash and cash equivalents ended at $66.5 million.
For 2026, the company expects net sales to grow 10% to 15% excluding the divested segment, and general and administrative expense to rise $3 million to $4 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Niagen Bioscience, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →